Menu
Mérieux Equity Partners is one of the most recognized and active European Investment firms in the Healthcare sector.
We support the development and growth of high-potential companies from business launch to large scale deployment through capital investment and tailor-made support based on our strong sector expertise and international network.
We are an agile investor with a flexible approach in terms of minority or majority stakes.
Our main focus is partnering with and investing alongside management teams.
With combined operational and investment experience in healthcare sector, the team is focusing on disruptive technology to bring transformative medical solutions to the patient. Since 2010, we invested in more than 25 companies, mainly in Europe (sweet spot), and the United States (opportunistic). Our active Venture Capital fund (OMX FPCI) is covering 4 Healthcare subsegment (Diagnostic & Therapeutic Platforms, Life Science Tools, Medical Devices, Pharma Services), invested in 12 companies so far. From seed to late venture, we support and strengthen the development and growth of the most promising European companies by supporting entrepreneurs across the entire development path. Our team and large network is bringing decades of experience in product development, manufacturing, regulatory and clinical affairs, intellectual property, as well as human resources management.
We have partnered with experts and organizations throughout the innovation chain to provide comprehensive support to entrepreneurs at all stages of development. Our mission is to identify and select the most promising companies for helping them successfully grow their impactful business. We believe that our partnership approach combined with our industrial network sets us apart as early stage investors, enabling us to provide unparalleled support to our entrepreneurs.
Through M2care, initially a French services company launched in 2017 dedicated to leverage health innovation, and which became a European startup studio in 2023.
Investment range
Investment range
Investment range
Investment range
Pertinence Invest 2 (“PI2”) is a seed fund launched in 2020 by UI Investissement (formerly Sofimac Innovation), in partnership with leading French engineering schools and universities. It focuses on Industry 4.0, new energies, new materials, digitalization, and disruptive platforms serving the health and nutrition sectors. This program brings together an entire ecosystem including some of France’s largest industrial companies (bioMérieux, Michelin, Seb, etc.) and supports startups directly from the research laboratories of its university partners or in direct relation with them.
Mérieux Equity Partners advises UI Investissement on investments in the healthcare and nutrition sectors for this fund. The fund’s strategy is to invest in highly innovative companies and leading platforms in early development stage with investments ranging from €0.3 million to €3 million.
Our Buyout team invests, majority or minority, in profitable and fast-growing European companies to support their projects and development
